Companies House true 2025-01-03 2026-01-31 false 16161663 uk-bus:Director1 2025-01-03 2026-01-31 16161663 uk-bus:Director2 2025-01-03 2026-01-31 16161663 2025-01-03 2026-01-31 16161663 2026-01-31 16161663 uk-bus:EntityHasNeverTraded 2025-01-03 2026-01-31 16161663 uk-bus:FRS102 2025-01-03 2026-01-31 16161663 uk-bus:FullAccounts 2025-01-03 2026-01-31 16161663 uk-bus:AuditExempt-NoAccountantsReport 2025-01-03 2026-01-31 16161663 uk-bus:OrdinaryShareClass1 2025-01-03 2026-01-31 16161663 uk-bus:OrdinaryShareClass2 2025-01-03 2026-01-31 16161663 uk-bus:OrdinaryShareClass3 2025-01-03 2026-01-31 16161663 uk-bus:PreferenceShareClass1 2025-01-03 2026-01-31 16161663 uk-bus:PreferenceShareClass2 2025-01-03 2026-01-31 16161663 uk-bus:PreferenceShareClass3 2025-01-03 2026-01-31 16161663 uk-core:ShareCapitalPreferenceShares 2026-01-31 iso4217:GBP iso4217:GBP xbrli:shares xbrli:shares

Registered Number 16161663

UK CONLAD BIOTECHNOLOGY CO., LTD

Dormant Accounts

31 January 2026

## UK CONLAD BIOTECHNOLOGY CO., LTD Registered Number 16161663

## Balance Sheet as at 31 January 2026

|  | 2026 |
--- | --- | --- | ---
|  | £ |
Called up share capital not paid |  | 10000 |
Net assets |  | 10000 |
Issued share capital
10000 10000 Shares of £ 1 each |  | 10000
Total Shareholder funds |  | 10000 |

### STATEMENTS

1. For the year ending 31 January 2026 the company was entitled to exemption under section 480 of the Companies Act 2006 relating to dormant companies.
2. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
3. The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
4. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 5 February 2026

And signed on their behalf by:
YUANFENG SHI, Director